Maxim Group Maintains Bullish Outlook in Athersys (ATHX) Despite Trial Failure and Massive Sell-Off
- Traders Eye Relational Investors Stocks on Wind Down
- David Tepper Talks Bonds, Stocks, Fannie/Freddie, Bill Gross and More
- Unusual 11 Mid-Day Movers 10/1: (ARDX) (ANGI) (TKMR) Higher; (LOOK) (WPRT) (SPEX) Lower
- CDC confirms first Ebola case diagnosed in the U.S. (TKMR)
- ADP Employment Change 213K vs 205K Expected
Maxim Group analyst Jason Kolbert reiterated a Buy rating on today's blow-up du jour Athersys (NASDAQ: ATHX) but lowered his price target from $10 to $7 after the company's and partner Pfizer (NYSE: PFE) trial failed to meet its endpoint in Ulcerative Colitis trial.
Kolbert said, "While we are disappointed, we are not totally surprised. This is because we have always felt the trial was aggressive, treating the most difficult patients (who had failed all other therapies) with Multistem. We have for the moment removed the UC indication from our model which lowers our price target to $7, from $10. Remember that this product is partnered with Pfizer so Athersys does not realize the full benefits of the product commercially."
The analyst is not backing away from this positive outlook on Athersys "as we still believe that we can see good data from the stroke trial." He added, "We believe the stroke trial (acute patients) remains the most significant near-term event for Athersys and should not be equated to results in chronic (UC) patients. Enrollment should be complete by this summer, and the stage is set for data this fall."
Shares of Athersys are down 54.4% into the close to $1.25.
You May Also Be Interested In
- UPDATE: Credit Suisse Downgrades Rush Enterprises Inc. (RUSHA) to Neutral
- BofA/Merrill Lynch Bullish on Canadian Pacific (CP) Following Buyback News and Into Analyst Day
- UPDATE: Credit Suisse Downgrades Tuesday Morning (TUES) to Neutral
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Related EntitiesMaxim Group
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!